Form D · Biotechnology
INTRA CELLULAR THERAPIES INC
New York, NY · CIK 0001176407
Offering snapshot reported Sep 11, 2013 · SEC filing
- Reported sold
- $60M Offering amount: $60M
- Investors reported
- 185 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Aug 29, 2013 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Sep 11, 2013 | Initial | $60,000,000 | No comparison | 185 | SEC filing |
| Jun 25, 2013 | Amendment | $15,289,893 | $0vs Apr 1, 2013 | 12 | SEC filing |
| Jun 25, 2013 | Initial | $241,633 | No comparison | 1 | SEC filing |
| May 17, 2013 | Amendment | $15,289,893 | $0vs Apr 1, 2013 | 12 | SEC filing |
| Apr 1, 2013 | Initial | $15,289,893 | No comparison | 12 | SEC filing |
| Mar 8, 2010 | Initial | $5,335,780 | No comparison | 10 | SEC filing |
| Nov 6, 2007 | Paper | Not reported | No comparison | Not reported | SEC filing |
| Feb 1, 2006 | Paper | Not reported | No comparison | Not reported | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06
- Duration over one year
- No
- Business combination
- Yes
- Sales commissions
- $2.91M (estimated)
- Finders' fees
- $0
- Form D file number
- 021-202684
Includes approximately $15.3 million in principal, plus accrued interest, from the conversion of outstanding convertible notes.
Will be paid in aggregate cash fee not to exceed $2,905,000.
Sales compensation recipients
Scroll to see all columns →
| Recipient | CRD | Associated broker-dealer |
|---|---|---|
| Leerink Swann LLC | 39011 | |
| National Securities Corporation | 7569 | |
| Livingston Securities, LLC | 147364 |
Source: Form D, filed Sep 11, 2013. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Christopher Alafi | Director |
| Allen Fienberg | Executive |
| Lawrence Hineline | Executive |
| David Kipnis | Director |
| Richard Lerner | Director |
| Joel Marcus | Director |
| Sharon Mates | Director, Executive |
| Sir Michael Rawlins | Director |
| Michael Rawlins | Director |
| Kimberly Vanover | Executive |
| Lawrence Wennogle | Executive |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
Audubon Biomedical Science & Technology Park, 3960 Broadway
New York, NY, 10032
New York, NY, 10032